Pelareorep - Oncolytics Biotech

Drug Profile

Pelareorep - Oncolytics Biotech

Alternative Names: PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus

Latest Information Update: 14 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncolytics Biotech
  • Developer Mayo Clinic; National Cancer Institute (Canada); National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Virus replication modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Fallopian tube cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Multiple myeloma
  • Preclinical Liver cancer; Viral hepatitis
  • No development reported Solid tumours

Most Recent Events

  • 12 Nov 2018 Oncolytics Biotech plans clinical trials for solid tumours and haematological malignancies (in combination therapy)
  • 24 Oct 2018 Oncolytics Biotech and Emory University initiates enrolment in a phase I trial for Multiple-myeloma(Combination therapy, Second line therapy or greater) in USA (NCT03605719)
  • 11 Oct 2018 Efficacy and adverse events data from a phase I trial in Colorectal cancer released by Oncolytics Biotech® (9252213; 9251562)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top